Correction to: Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
作者信息
Lane Samantha, Shakir Saad
机构信息
Institute of Pharmacovigilance Sciences, Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, UK.
School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
出版信息
Drug Saf. 2022 Nov;45(11):1439-1440. doi: 10.1007/s40264-022-01233-9.
Abstract
摘要
相似文献
1
Correction to: Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.对《评估英国接种阿斯利康新冠疫苗（Vaxzevria）后并发血小板减少症的血栓形成病例的病死率：对自发报告数据的回顾》的勘误
Drug Saf. 2022 Nov;45(11):1439-1440. doi: 10.1007/s40264-022-01233-9.
2
Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.评估英国阿斯利康（Vaxzevria）新冠疫苗接种后并发血小板减少症的血栓病例病死率：自发报告数据综述。
Drug Saf. 2022 Sep;45(9):1003-1008. doi: 10.1007/s40264-022-01217-9. Epub 2022 Aug 4.
3
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure.接种阿斯利康“新冠疫苗”后出现血小板减少症和颅内静脉窦血栓形成
J Clin Med. 2021 Apr 9;10(8):1599. doi: 10.3390/jcm10081599.
4
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.2021 年 5 月至 9 月期间，法国开展了一项关于 COVID-19 疫苗 Vaxzevria 不同用途的获益与风险的建模研究。
Euro Surveill. 2021 Jul;26(26). doi: 10.2807/1560-7917.ES.2021.26.26.2100533.
5
AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy.阿斯利康ChAdOx1-S型新冠疫苗可安全用于对乙二胺四乙酸（EDTA）过敏的患者。
Allergy Asthma Clin Immunol. 2022 Mar 10;18(1):22. doi: 10.1186/s13223-022-00665-3.
6
Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres.与VaxZevria®（阿斯利康）疫苗相关的非典型血栓形成：来自法国地区药物警戒中心网络的数据。
Therapie. 2021 Jul-Aug;76(4):369-373. doi: 10.1016/j.therap.2021.05.007. Epub 2021 May 19.
7
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET).既往接种过Vaxzevria（阿斯利康）疫苗的受试者中与血小板减少相关的脑静脉和内脏静脉血栓形成的管理：意大利止血与血栓形成研究学会（SISET）的立场声明
Blood Transfus. 2021 Jul;19(4):281-283. doi: 10.2450/2021.0117-21. Epub 2021 Apr 15.
8
Increment of D-dimer Associated with Immune Thrombotic Thrombocytopenia in ChAdOx1 nCoV-19 Vaccinated Individuals.腺病毒载体新冠疫苗接种者的 D-二聚体升高与免疫性血栓性血小板减少症相关。
Arch Med Res. 2022 Jun;53(4):341-351. doi: 10.1016/j.arcmed.2022.03.008. Epub 2022 May 6.
9
Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines.疫苗诱导的血栓性血小板减少症：血栓形成与基于腺病毒的 SARS-CoV-2 疫苗之间难以捉摸的联系。
Intern Emerg Med. 2021 Aug;16(5):1113-1119. doi: 10.1007/s11739-021-02793-x. Epub 2021 Jun 30.
10
Severe thrombocytopenia after Vaxzevria vaccination in a single patient: A case report.1例接种Vaxzevria疫苗后出现严重血小板减少症：病例报告
SAGE Open Med Case Rep. 2022 Apr 17;10:2050313X221091407. doi: 10.1177/2050313X221091407. eCollection 2022.
Zotero 插件